# Polaris Group clinical trials: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Polaris Group as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Polaris Group: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/polaris-group

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 6, 2023 | NCT05842512 | Study of ADI-PEG 20 Versus Placebo in Subjects With NASH | Polaris Group | Phase 2 | Recruiting | Nonalcoholic Steatohepatitis (NASH) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05842512) |
| February 3, 2023 | NCT05712694 | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Polaris Group | Phase 3 | Terminated | Soft Tissue Sarcoma | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05712694) |
| April 8, 2022 | NCT05317819 | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma | Polaris Group | Phase 3 | Recruiting | Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05317819) |
| August 12, 2021 | NCT05001828 | Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia | Polaris Group | Phase 1 | Active not recruiting | Acute Myeloid Leukemia, Adult | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05001828) |
| October 14, 2020 | NCT04587830 | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme | Polaris Group | Phase 2 | Active not recruiting | Glioblastoma Multiforme (GBM) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04587830) |
| August 18, 2017 | NCT03254732 | Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers | Polaris Group | Phase 1 | Terminated | Advanced Solid Cancers | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03254732) |
| August 23, 2016 | NCT02875093 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | Polaris Group | Phase 1 | Terminated | Acute Myeloid Leukemia | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02875093) |
| March 16, 2016 | NCT02709512 | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin | Polaris Group | Phase 2/3 | Completed | Mesothelioma | 249 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02709512) |
| April 2, 2014 | NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | Polaris Group | Phase 1/2 | Terminated | Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02102022) |
| April 2, 2014 | NCT02101593 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | Polaris Group | Phase 1 | Completed | Hepatocellular Carcinoma | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02101593) |
| April 2, 2014 | NCT02101580 | Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer | Polaris Group | Phase 1 | Completed | Advanced Pancreatic Cancer | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02101580) |
| January 8, 2014 | NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin | Polaris Group | Phase 1 | Terminated | Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02029690) |
| December 9, 2013 | NCT02006030 | Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular... | Polaris Group | Phase 2 | Completed | Unresectable Hepatocellular Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02006030) |
| September 24, 2013 | NCT01948843 | Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer | Polaris Group | Phase 1 | Completed | HER2 Negative Metastatic Breast Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01948843) |
| July 29, 2013 | NCT01910025 | PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy | Polaris Group | Phase 2 | Completed | Non-Hodgkin's Lymphoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01910025) |
| July 29, 2013 | NCT01910012 | PH 2 ADI-PEG 20 Acute Myeloid Leukemia | Polaris Group | Phase 2 | Completed | Acute Myeloid Leukemia | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01910012) |
| August 15, 2012 | NCT01665183 | Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma | Polaris Group | Phase 1 | Completed | Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01665183) |
| February 8, 2012 | NCT01528384 | Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient | Polaris Group | Phase 1 | Completed | Argininosuccinate Synthetase Deficient | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01528384) |
| December 23, 2011 | NCT01497925 | Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer | Polaris Group | Phase 1 | Completed | Solid Tumors, Prostate Cancer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01497925) |
| February 1, 2011 | NCT01287585 | Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy | Polaris Group | Phase 3 | Completed | Hepatocellular Carcinoma | 636 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01287585) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 11 |
| Terminated | 5 |
| Active not recruiting | 2 |
| Recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Hepatocellular | 5 |
| Leukemia, Myeloid, Acute | 3 |
| Uveal Melanoma | 2 |
| Mesothelioma | 1 |
| Mesothelioma, Malignant | 1 |
| Prostatic Neoplasms | 1 |
| Melanoma | 1 |
| Ovarian Neoplasms | 1 |
| Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Glioblastoma | 1 |
| Glioma | 1 |
| Carcinoma | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Sarcoma | 1 |
| Leiomyosarcoma | 1 |
| Non-alcoholic Fatty Liver Disease | 1 |
| Liver Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Woodworking supply stores in the United States](https://specstream.ai/data/businesses/woodworking-supply-stores/united-states)
- [Whiskey bars in the United States](https://specstream.ai/data/businesses/whiskey-bars/united-states)
- [Waste collection companies in the United States](https://specstream.ai/data/businesses/waste-collection-companies/united-states)
- [Vegetarian restaurants in the United States](https://specstream.ai/data/businesses/vegetarian-restaurants/united-states)
- [Truck repair shops in the United States](https://specstream.ai/data/businesses/truck-repair-shops/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
